Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSpruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
46.665 USD -2.67 ( 5.42%)
Last update at 2026-11-10T21:00:00Z
VOLUME
72372
Market Cap
27.89M

Momentum Score

…

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
44.74
Low
48.30
High
52 Week Price Range
0.67
Low
5.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and genetic diseases. Long-term growth may be driven by advancement of clinical programs toward approvals, partnerships or licensing, and commercialization in niche markets, which could appeal to investors if trials succeed.
Material risks include clinical or regulatory failure, limited operating history with recurring losses and likely need for additional financing, plus execution challenges in commercializing therapies for small patient populations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
49.34
Dividend Yield
-
Revenue TTM
10.13M
Revenue Per Share
0.25
Gross Profit TTM
0.00M
Debt / Equity
0.06
ROE
-53.55%
Net Debt
-91.73M
ROCE
-59.49%
Diluted EPS TTM
-1.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.18M -42.29M -29.54M -13.09M -9.86M
Net income -45.08M -42.69M -30.03M -13.24M -9.86M
Selling general administrative 12.09M 11.37M 5.56M 2.29M 1.57M
Reconciled depreciation 0.07M 0.07M 0.04M 0.01M 0.00M
Ebit -47.28M -42.07M -29.42M -13.11M -9.86M
Ebitda -45.76M -41.95M -29.22M -13.01M -9.86M
Depreciation and amortization 1.52M 0.12M 0.20M 0.10M 0.00M
Non operating income net other 1.52M - 0.20M - -
Operating income -47.28M -42.07M -29.42M -13.11M -9.97M
Other operating expenses 47.28M 42.07M 29.42M 13.11M 9.97M
Interest expense 0.42M 0.34M 0.32M 0.07M 0.00M
Interest income 1.52M - - - -
Net interest income 1.10M -0.34M -0.32M -0.07M 0.00M
Income tax expense -1.10M 0.40M 0.49M 0.15M 0.11M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 47.28M 42.07M 29.42M 13.11M 9.97M
Total other income expense net 1.10M -0.23M -0.12M 0.02M 0.11M
Net income from continuing ops -46.18M -42.29M -29.54M -13.09M -9.86M
Net income applicable to common shares -46.18M -42.29M -29.54M -13.09M -9.86M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 103.95M 85.65M 126.49M 162.88M 4.69M
Other current assets 5.84M 1.21M 0.40M 0.28M 0.51M
Total liab 27.44M 17.16M 15.12M 13.46M 35.33M
Total stockholder equity 76.51M 68.49M 111.37M 149.43M -30.64M
Other current liab 14.35M 9.40M 5.69M 3.58M 1.17M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -197.23M -149.31M -103.13M -60.84M -31.30M
Other liab - 0.16M 0.07M 0.12M 0.02M
Other assets 0.00M 0.64M 0.51M 0.00M 0.04M
Cash 96.34M 24.49M 42.75M 157.15M 3.92M
Total current liabilities 24.46M 12.45M 8.87M 9.76M 4.30M
Current deferred revenue 4.91M - - - -
Net debt -91.73M -18.31M -36.58M -151.02M 0.52M
Short term debt 1.87M 1.62M 0.36M 2.55M 1.25M
Short long term debt 1.62M 1.62M - 2.55M 1.25M
Short long term debt total 4.61M 6.18M 6.17M 6.13M 4.45M
Other stockholder equity 273.74M 218.35M 214.69M 210.27M 0.66M
Property plant equipment - 1.40M 1.62M 1.79M -
Total current assets 102.18M 83.61M 91.89M 160.40M 4.65M
Long term investments - 0.00M 32.46M - -
Net tangible assets - 68.49M 111.37M 149.43M -30.64M
Short term investments 0.00M 54.59M 46.22M - -
Long term debt 1.72M 3.29M 4.88M 1.92M 3.19M
Accounts payable 3.33M 1.43M 2.82M 3.63M 1.88M
Accumulated other comprehensive income 0.00M -0.56M -0.18M -162.88M -
Common stock total equity - 0.00M - 0.00M 0.00M
Retained earnings total equity - -149.31M - -60.84M -
Non currrent assets other 0.55M 55.18M 0.65M 0.69M 0.04M
Non current assets total 1.76M 2.04M 34.59M 2.49M 0.04M
Capital lease obligations 1.27M 1.40M 1.65M 1.65M -
Long term debt total - 3.29M - 1.92M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 23.70M -79.08M -0.07M -0.00M -79.08M
Change to liabilities 1.86M 1.15M 3.73M -0.23M 1.70M
Total cashflows from investing activities 23.69M -79.17M -0.07M -0.00M -0.00M
Net borrowings - 0.23M 0.23M 4.50M 4.50M
Total cash from financing activities -0.24M 0.64M 181.03M 12.43M 12.43M
Change to operating activities 2.53M 0.81M -2.57M 0.49M -0.51M
Net income -46.18M -42.29M -29.54M -13.09M -9.86M
Change in cash -18.23M -114.40M 153.44M -0.19M -8.57M
Begin period cash flow 42.96M 157.37M 3.92M 4.11M 12.68M
End period cash flow 24.73M 42.96M 157.37M 3.92M 4.11M
Total cash from operating activities -41.68M -35.88M -27.52M -12.62M -8.57M
Issuance of capital stock - 0.00M 183.89M 7.94M 0.00M
Depreciation 0.07M 0.07M 0.04M 0.01M 0.00M
Sale purchase of stock 0.08M 0.13M 93.40M - -
Other cashflows from financing activities -0.32M 5.28M 84.78M -0.00M -0.01M
Change to netincome 3.67M 4.39M 0.82M 0.20M 0.10M
Capital expenditures 0.01M 0.09M 0.07M 0.00M 0.00M
Cash flows other operating -1.12M - -2.82M - -
Cash and cash equivalents changes -18.23M - 153.44M - -
Change in working capital 1.13M 1.96M 1.16M 0.26M 1.19M
Stock based compensation 3.63M 3.96M 0.76M 0.20M 0.10M
Other non cash items -0.34M 0.31M 0.07M 1.98M -
Free cash flow -41.69M -35.97M -27.59M -12.62M -8.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SPRB
Spruce Biosciences, Inc. Common Stock		 -2.67
5.42%		 46.66 - - 3.00 0.40 15.32 1.30
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Spruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

611 Gateway Boulevard, South San Francisco, CA, United States, 94080

415 655 4168

https://www.sprucebiosciences.com

22

Name Title Year Born
Mr. Michael G. Grey Exec. Chairman 1953
Mr. Samir M. Gharib CPA, CPA, M.B.A. Pres & CFO 1982
Dr. Javier Szwarcberg M.D., M.P.H. CEO & Director 1970
Dr. Ralph William Charlton III, M.D. Chief Medical Officer 1970
Dr. Libbie Mansell M.B.A., Ph.D. Chief Regulatory & Quality Officer NA
Ms. P. J. Ramtin Sr. VP of Bus. Operations NA
Mr. Michael G. Grey Executive Chairman 1953
Mr. Samir M. Gharib C.P.A., M.B.A. President & CFO 1982
Ms. P. J. Ramtin Senior Vice President of Business Operations NA
Ms. Heidi Petersen M.P.H. Senior Vice President of Regulatory & Quality NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…